company background image
FULC

Fulcrum Therapeutics NasdaqGM:FULC Stock Report

Last Price

US$6.25

Market Cap

US$325.3m

7D

-4.6%

1Y

-59.3%

Updated

07 Dec, 2022

Data

Company Financials +
FULC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

FULC Stock Overview

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.

Fulcrum Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Fulcrum Therapeutics
Historical stock prices
Current Share PriceUS$6.25
52 Week HighUS$24.79
52 Week LowUS$3.21
Beta1.95
1 Month Change8.13%
3 Month Change-21.29%
1 Year Change-59.28%
3 Year Change-51.59%
5 Year Changen/a
Change since IPO-53.70%

Recent News & Updates

What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today

Nov 17
What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today

Recent updates

What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today

Nov 17
What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today

We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate

Oct 18
We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate

Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts

Aug 13
Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts

These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat

May 10
These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat

Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth

Apr 09
Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth

Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Dec 09
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results

Aug 12
Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results

News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts

Aug 11
News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts

Industry Analysts Just Upgraded Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Revenue Forecasts By 83%

May 12
Industry Analysts Just Upgraded Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Revenue Forecasts By 83%

We're Hopeful That Fulcrum Therapeutics (NASDAQ:FULC) Will Use Its Cash Wisely

May 07
We're Hopeful That Fulcrum Therapeutics (NASDAQ:FULC) Will Use Its Cash Wisely

Could The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Ownership Structure Tell Us Something Useful?

Feb 05
Could The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Ownership Structure Tell Us Something Useful?

Introducing Fulcrum Therapeutics (NASDAQ:FULC), A Stock That Climbed 12% In The Last Year

Dec 14
Introducing Fulcrum Therapeutics (NASDAQ:FULC), A Stock That Climbed 12% In The Last Year

Shareholder Returns

FULCUS PharmaceuticalsUS Market
7D-4.6%0.5%-0.4%
1Y-59.3%13.2%-20.6%

Return vs Industry: FULC underperformed the US Pharmaceuticals industry which returned 15% over the past year.

Return vs Market: FULC underperformed the US Market which returned -17.6% over the past year.

Price Volatility

Is FULC's price volatile compared to industry and market?
FULC volatility
FULC Average Weekly Movement11.7%
Pharmaceuticals Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: FULC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: FULC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2015104Bryan Stuarthttps://www.fulcrumtx.com

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases.

Fulcrum Therapeutics, Inc. Fundamentals Summary

How do Fulcrum Therapeutics's earnings and revenue compare to its market cap?
FULC fundamental statistics
Market CapUS$325.32m
Earnings (TTM)-US$107.22m
Revenue (TTM)US$10.72m

30.4x

P/S Ratio

-3.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FULC income statement (TTM)
RevenueUS$10.72m
Cost of RevenueUS$72.67m
Gross Profit-US$61.96m
Other ExpensesUS$45.26m
Earnings-US$107.22m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.06
Gross Margin-578.23%
Net Profit Margin-1,000.65%
Debt/Equity Ratio0%

How did FULC perform over the long term?

See historical performance and comparison